Enterprise News

The company was successively awarded New Veterinary Registration Certificates of three vaccines including the “porcine circovirus type 2 (ZJ / C strain) inactivated vaccine”.

At the beginning of 2013, the company was successively awarded New Veterinary Registration Certificates of three vaccines including porcine circovirus type 2 (ZJ / C strain) inactivated vaccine developed in cooperation with the Key Laboratory of Virology of the Ministry of Agriculture, Zhejiang University; three types of new veterinary drug of duck infectious serositis bivalent inactivated vaccine (type 1 SG4strain+type 2 ZZY7strain) developed in cooperation with China Agricultural University; two types of new veterinary drug of duck hepatitis live vaccine developed in cooperation with Anhui Animal Science Institute of Academy of Agricultural Sciences, Jiangsu Veterinary Research Institute of Academy of Agricultural Sciences and National Research Center of Veterinary Biologicals engineering and technology.

In terms of the three new veterinary products, EBVAC is the first company in China which has passed the production quality re-inspection of duck infectious serositis bivalent inactivated vaccine (type 1 SG4strain+type 2 ZZY7strain) and porcine circovirus type 2 (ZJ / C strain) inactivated vaccine as well as the first company which has been awarded the production approval number of the aforementioned two vaccines. At present, the duck hepatitis live vaccine (A66 strain) has also entered the stage of production number declaration. New products are expected to be launched from April.

As the above-mentioned new products coming into the market, the series of porcine vaccine and poultry vaccine products of our company will be further improved. At present, the company has a total variety of 12 porcine vaccine products involving porcine circovirus type 2 (ZJ / C strain) inactivated vaccine, porcine reproductive and respiratory syndrome live vaccine (CH-1R strain), porcine reproductive and respiratory syndrome inactivated vaccine (NVDC-JXA1 strains), infectious gastroenteritis and porcine epidemic diarrhea bivalent inactivated vaccine; in addition to the preexisting chicken vaccines, poultry vaccine products in the company cover three featured duck vaccine products such as duck infectious serositis bivalent vaccine (type 1 SG4 strains + type2 ZZY, strain), duck hepatitis live vaccine (A66 strain) and duck plague live vaccine.

The company will adhere to the core values of “Innovation, Evolution and Quality”, value implementation, pay attention to details, put efforts in continuous improvement, produce every product in a thoroughgoing manner and constantly provide customers with qualified products and professional services.

Related News

  • •  The company’s 1st Zhejiang Partner Technical Forum and “Yuanjingnuo (PCV type II)” Launch Conference was successfully held

    With willows swaying in the wind and trees shading the street, the spring has come to Hangzhou. From April 13 to 14, the company held its first Zhejiang Partner Technical Forum and “Yuanjingnuo” Launch Conference. Famous industry experts, leaders of the Animal Husbandry and Veterinary Bureau and Animal Disease Control Center, entrepreneurs of large ranch, technicians and dealersdistributors of EBVAC participated in the conference and celebrated the successful launch of Yuanjingnuo. During the conference, Professor Zhou Jiyong, the designer of porcine circovirus ZJ / C strains and Director of Animal Virology of the Ministry of Agriculture Key Laboratory of Zhejiang University, Researcher Wang Yicheng, Director of the Swine Disease Research Center of Zhejiang Academy of Agricultural Sciences and Professor Li Baochen, General Manager of the company delivered report to the participants.

  • •  EBVAC Yuanjingnuo is now on sale

    EBVAC new featured product “Yuanjingnuo”- porcine circovirus type 2 inactivated vaccine (ZJ / C strain) has achieved the new veterinary drug registration certificates and veterinary approval number of Ministry of Agriculture and will be launched in the spring of 2013.

  • •  To establish a first-class, independent and innovative new enterprise EBVAC is setting sail

    “Innovation, Evolution and Quality”, since its inception, EBVAC has been steadfastly working on independent innovation. In order to develop high-quality animal vaccine products, apart from establishing the first-class R&D Center within the industry (identified as Zhejiang high-tech R&D Center in 2009), the company has been actively looking for benchmark and gaps with its competitors, adopting innovative ideology from other outstanding enterprises and bringing in a large number of industry elites with innovation capacity. Through years of efforts, the company has created a number of products with intellectual property rights as well as innovations in processing.

  • •  The company participated in the 5th International Conference on Vaccine Antibody

    From March 18 to 20, 2013, leaders of EBVAC R&D Center and technical managers of all departments participated in the 5th International Conference on Vaccine Antibody held in Hangzhou.

  • •  Delegation from Doumen District in Zhuhai City visited our company for research

    On 15th March 2013, delegation from Doumen District in Zhuhai City accompanied by relevant readers of Xiasha Economic and Technological Development Zone, visited our company for investigation. During the investigation, Manger Lv briefly introduced the positioning development, corporate culture and values, quality pursuit and market expansion of the company. The company management conducted in-depth discussions with the members of the delegation on issues such as biosafety control, declaration for new veterinary and application for government-funded projects.

  • •  Always be alert

    -Record of EBVAC Safety Work Conference in the First Quarter of 2013